Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2019 | Apr. 29, 2019 | |
Document And Entity Information [Abstract] | ||
Entity Registrant Name | Pulse Biosciences, Inc. | |
Entity Filer Category | Accelerated Filer | |
Entity Central Index Key | 0001625101 | |
Trading Symbol | plse | |
Amendment Flag | false | |
Document Type | 10-Q | |
Document Fiscal Period Focus | Q1 | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Current Fiscal Year End Date | --12-31 | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | true | |
Entity Small Business | true | |
Entity Common Stock, Shares Outstanding | 20,710,406 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash and cash equivalents | $ 8,536 | $ 51,103 |
Investments | 44,265 | 8,480 |
Prepaid expenses and other current assets | 550 | 779 |
Total current assets | 53,351 | 60,362 |
Property and equipment, net | 2,056 | 2,173 |
Intangible assets, net | 5,046 | 5,213 |
Goodwill | 2,791 | 2,791 |
Other asset | 208 | 101 |
Total assets | 63,452 | 70,640 |
Current liabilities: | ||
Accounts payable | 1,200 | 1,272 |
Accrued expenses | 1,519 | 1,421 |
Deferred rent, current | 415 | |
Lease liability, current | 396 | |
Total current liabilities | 3,115 | 3,108 |
Deferred rent, less current | 1,198 | |
Lease liability, less current | 1,223 | |
Total liabilities | 4,338 | 4,306 |
Commitments and contingencies (Note 10) | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value; authorized – 50,000 shares; no shares issued and outstanding | ||
Common stock, $0.001 par value: authorized – 500,000 shares; issued and outstanding – 20,710 shares and 20,593 shares at March 31, 2019 and December 31, 2018, respectively | 21 | 21 |
Additional paid-in-capital | 144,887 | 142,032 |
Accumulated other comprehensive income (loss) | 2 | (1) |
Accumulated deficit | (85,796) | (75,718) |
Total stockholders' equity | 59,114 | 66,334 |
Total liabilities and stockholders' equity | $ 63,452 | $ 70,640 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2019 | Dec. 31, 2018 |
Condensed Consolidated Balance Sheets [Abstract] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 50,000,000 | 50,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 500,000,000 | 500,000,000 |
Common stock, shares issued | 20,710,000 | 20,593,000 |
Common stock, shares outstanding | 20,710,000 | 20,593,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements Of Operations And Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Condensed Consolidated Statements Of Operations And Comprehensive Loss [Abstract] | ||
Revenue | ||
Operating expenses: | ||
General and administrative | 4,401 | 5,383 |
Research and development | 5,842 | 3,175 |
Amortization of intangible assets | 167 | 166 |
Total operating expenses | 10,410 | 8,724 |
Other income (expense): | ||
Interest income | 332 | 56 |
Total other income (expense) | 332 | 56 |
Net loss | (10,078) | (8,668) |
Other comprehensive loss: | ||
Unrealized gain on available-for-sale securities | 3 | 48 |
Comprehensive loss | $ (10,075) | $ (8,620) |
Net loss per share: | ||
Basic and diluted net loss per share | $ (0.49) | $ (0.51) |
Weighted average shares used to compute net loss per common share - basic and diluted | 20,679 | 16,842 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Cash flows from operating activities: | ||
Net loss | $ (10,078) | $ (8,668) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 162 | 153 |
Amortization of intangible assets | 167 | 166 |
Stock-based compensation | 2,361 | 3,420 |
Net premium amortization and discount on available-for-sale securities | (96) | (10) |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other current assets | 229 | 44 |
Other long-term assets | (107) | |
Accounts payable | (72) | 162 |
Accrued expenses | 98 | (188) |
Other current and long-term liabilities | 6 | (97) |
Net cash used in operating activities | (7,330) | (5,018) |
Cash flows from investing activities: | ||
Purchases of property and equipment | (45) | (34) |
Purchases of investments | (44,186) | (19,157) |
Maturities of investments | 8,500 | 6,315 |
Sales of investments | 24,875 | |
Net cash provided by (used in) investing activities | (35,731) | 11,999 |
Cash flows from financing activities: | ||
Proceeds from issuance of common stock under employee stock purchase plan | 272 | 188 |
Proceeds from exercises of stock options | 222 | 112 |
Net cash provided by financing activities | 494 | 300 |
Net increase (decrease) in cash | (42,567) | 7,281 |
Cash and cash equivalents at beginning of period | 51,103 | 3,386 |
Cash and cash equivalents at end of period | 8,536 | 10,667 |
Supplemental disclosure of noncash investing and financing activities: | ||
Change in unrealized gains (losses) on available-for-sale securities | $ 3 | $ 48 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands | Common Stock | Additional Paid-in Capital [Member] | Accumulated Other Comprehensive Income (Loss) [Member] | Accumulated Deficit [Member] | Total |
Balance at Dec. 31, 2017 | $ 17 | $ 84,202 | $ (51) | $ (38,173) | $ 45,995 |
Balance, shares at Dec. 31, 2017 | 16,819 | ||||
Issuance of shares upon exercise of stock options | 112 | 112 | |||
Issuance of shares upon exercise of stock options, shares | 38 | ||||
Issuance of shares under employee stock purchase plan | 188 | 188 | |||
Issuance of shares under employee stock purchase plan, shares | 12 | ||||
Stock-based compensation expense | 3,420 | 3,420 | |||
Unrealized gain on available-for-sale securities | 48 | 48 | |||
Net loss | (8,668) | (8,668) | |||
Balance at Mar. 31, 2018 | $ 17 | 87,922 | (3) | (46,841) | 41,095 |
Balance, shares at Mar. 31, 2018 | 16,869 | ||||
Balance at Dec. 31, 2018 | $ 21 | 142,032 | (1) | (75,718) | $ 66,334 |
Balance, shares at Dec. 31, 2018 | 20,593 | 20,593 | |||
Issuance of shares upon exercise of stock options | 272 | $ 272 | |||
Issuance of shares upon exercise of stock options, shares | 99 | ||||
Issuance of shares under employee stock purchase plan | 222 | 222 | |||
Issuance of shares under employee stock purchase plan, shares | 18 | ||||
Stock-based compensation expense | 2,361 | 2,361 | |||
Unrealized gain on available-for-sale securities | 3 | 3 | |||
Net loss | (10,078) | (10,078) | |||
Balance at Mar. 31, 2019 | $ 21 | $ 144,887 | $ 2 | $ (85,796) | $ 59,114 |
Balance, shares at Mar. 31, 2019 | 20,710 | 20,710 |
Description Of The Business
Description Of The Business | 3 Months Ended |
Mar. 31, 2019 | |
Description Of The Business [Abstract] | |
Description Of The Business | 1. Description of the Business Pulse Biosciences, Inc., is a bioelectric medicine company pursuing commercial introduction of its proprietary CellFX™ System utilizing the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) platform technology. The Company’s NPS technology provides a novel, precise, non-thermal cellular treatment technology delivering nanosecond pulses of high amplitude electrical energy that clear targeted cells while sparing adjacent non-cellular tissue. The novel characteristics of the Company’s NPS mechanism of action has the potential to significantly benefit patients across multiple medical applications, including dermatology, the Company’s first planned commercial application. The Company was incorp orated in Nevada on May 19, 2014 . O n June 18, 2018, the Company reincorporated from the State of Nevada to the State of Delaware. The Company’s headquarters and research facility are located in Hayward, California. The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company has not yet commenced revenue-generating operations, does not have cash flows from operations, and will need to raise additional capital to finance its operations. There can be no assurances that the Company will be able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its operating requirements. |
Summary Of Significant Accounti
Summary Of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2019 | |
Summary Of Significant Accounting Policies [Abstract] | |
Summary Of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements (“Financial Statements”) have been prepared on a basis consistent with the Company’s December 31, 2018 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Financial Statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated balance sheet as of December 31, 2018 was derived from the audited consolidated financial statements as of that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. The results of operations for the three-month period ended March 31, 2019 are not necessarily indicative of the results to be expected for the entire year or any future periods. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes to the Financial Statements. Estimates include, but are not limited to, the valuation of cash equivalents and investments, the valuation and recognition of share-based compensation and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates. Recently Adopted Accounting Pronouncement In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“Topic 842”), which amended prior accounting standards for leases. The Company adopted Topic 842 on January 1, 2019, using the transition method per ASU No. 2018-11 issued on July 2018 wherein entities were allowed to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Accordingly, all periods prior to January 1, 2019 were presented in accordance with the previous ASC 840, Leases, and no retrospective adjustments were made to the comparative periods presented. The adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets (“ROU”) presented within other assets and operating lease liabilities of approximately $0.1 million as of January 1, 2019. The adoption did not materially impact the Company’s Consolidated Statement of Stockholders’ Equity or Cash Flows. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies during the three-month period ended March 31, 2019, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, except for the adoption of ASU No. 2016-02, Leases , as of January 1, 2019. Principles of Consolidation The accompanying consolidated financial statements include the financial statements of Pulse Biosciences and its wholly-owned subsidiaries. Intercompany balances and transactions, if any, have been eliminated in consolidation. Net Loss per Share The Company calculates basic net loss per share by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share. Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive. The following outstanding stock options, warrants and restricted stock units were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three-Month Periods Ended March 31, 2019 2018 Common stock warrants 213,485 249,709 Common stock options 2,871,770 2,598,754 Restricted stock units 222,606 229,774 Total 3,307,861 3,078,237 Reclassification Certain items in prior period financial statements have been reclassified to conform to the presentation in the current period financial statements. Such reclassifications did not impact the Company's previously reported net loss or financial position. |
Fair Value Of Financial Instrum
Fair Value Of Financial Instruments | 3 Months Ended |
Mar. 31, 2019 | |
Fair Value Of Financial Instruments [Abstract] | |
Fair Value Of Financial Instruments | 3. Fair Value of Financial Instruments The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value of financial instruments into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Level 1 - Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include money market funds. Level 2 - Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include commercial paper, corporate bonds, and asset-backed securities. Level 3 - Unobservable inputs for which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. The Company did not classify any of its investments within Level 3 of the fair value hierarchy. The following table sets forth the fair value of the Company’s financial assets measured on a recurring basis as of March 31, 2019 and December 31, 2018, respectively (in thousands): March 31, 2019 December 31, 2018 Assets Classification Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Money market funds Cash and cash equivalents $ 7,773 — — $ 7,773 $ 50,703 $ — $ — $ 50,703 U.S. Treasury Securities Investments — 44,265 — 44,265 — 8,480 — 8,480 Total assets measured at fair value $ 7,773 $ 44,265 $ — $ 52,038 $ 50,703 $ 8,480 $ — $ 59,183 The Company did not have any financial liabilities measured on a recurring basis as of March 31, 2019 or December 31, 2018. During the three-month period ended March 31, 2019, there were no transfers between Level 1, Level 2 or Level 3 assets or liabilities reported at fair value on a recurring basis and the valuation techniques used did not change compared to the Company’s established practice. |
Property And Equipment, Net
Property And Equipment, Net | 3 Months Ended |
Mar. 31, 2019 | |
Property And Equipment, Net [Abstract] | |
Property And Equipment, Net | 4. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): March 31, December 31, 2019 2018 Leasehold improvements $ 2,248 $ 2,248 Laboratory equipment 589 518 Furniture, fixtures, and equipment 256 248 Software 117 118 Construction in progress — 33 3,210 3,165 Less: Accumulated depreciation (1,154) (992) $ 2,056 $ 2,173 Depreciation expense was $0.2 million and $0.2 million for th e three-month periods ended March 31, 2019 and 2018, respectively. |
Intangible Assets, Net
Intangible Assets, Net | 3 Months Ended |
Mar. 31, 2019 | |
Intangible Assets, Net [Abstract] | |
Intangible Assets, Net | 5 . Intangible Assets, Net Intangible assets primarily consist of acquired licenses to utilize certain patents, know-how and technology relating to the Company’s NPS for biomedical applications acquired from Old Dominion University Research Foundation (“ODURF”), Eastern Virginia Medical School, and the University of Southern California. In addition, the Company entered into a Sponsored Research Agreement with Old Dominion University’s Frank Reidy Research Center for Bioelectrics, which includes certain intellectual property rights arising from the research. The Company is amortizing the intangible assets over an estimated useful life of 12 years. Intangible assets, net consisted of the following (in thousands): March 31, December 31, 2019 2018 Acquired patents and licenses $ 7,985 $ 7,985 Less: Accumulated amortization (2,939) (2,772) $ 5,046 $ 5,213 A schedule of the amortization of intangible assets for the remainder of 2019 and the succeeding five fiscal years and thereafter is as follows (in thousands): Year Ending December 31: 2019 (remaining 9 months) $ 499 2020 665 2021 665 2022 665 2023 665 2024 665 Thereafter 1,222 $ 5,046 |
Goodwill
Goodwill | 3 Months Ended |
Mar. 31, 2019 | |
Goodwill [Abstract] | |
Goodwill | 6. Goodwill During 2014, the Company acquired three companies (the “acquisitions”) for aggregate consideration of $5.5 million. In accordance with ASC Topic 805, Business Combinations , the Company recorded goodwill of $2.8 million in connection with the acquisitions as the consideration paid exceeded the fair value of the net tangible assets and the intangible assets acquired. The Company reviews goodwill for impairment at least annually or whenever changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. Based on the Company’s annual impairment test as of December 31, 2018 the Company determined that no impairment of goodwill existed and was not aware of any indicators of impairment at such date. In addition, there were no indicators of impairment at March 31, 2019. |
Accrued Expenses
Accrued Expenses | 3 Months Ended |
Mar. 31, 2019 | |
Accrued Expenses [Abstract] | |
Accrued Expenses | 7. Accrued Expenses Accrued expenses consisted of the following (in thousands): March 31, December 31, 2019 2018 Compensation expense $ 672 $ 938 Accrued clinical 429 156 Professional fees 315 274 Supplies 28 53 Other 75 — $ 1,519 $ 1,421 |
Stockholders' Equity And Stock-
Stockholders' Equity And Stock-Based Compensation | 3 Months Ended |
Mar. 31, 2019 | |
Stockholders' Equity And Stock-Based Compensation [Abstract] | |
Stockholders' Equity And Stock-Based Compensation | 8. Stockholders’ Equity and Stock-Based Compensation Rights Offering On October 25, 2018, the Company commenced a rights offering pursuant to which stockholders of record as of November 19, 2018, were issued, at no charge, one subscription right for each share of common stock then outstanding. Each right entitled the holder to purchase 0.19860755 share of the Company’s common stock for $12.57 per share (the “Rights Offering”). Stockholders who exercised their rights in full were also permitted an over-subscription right to purchase additional shares of common stock that remained unsubscribed at the expiration of the Rights Offering, subject to the availability of shares and a pro rata allocation of shares among persons exercising the oversubscription right. Upon the closing of the Rights Offering on December 6, 2018, the Rights Offering was oversubscribed. A total of 3,581,148 shares of the Company’s common stock were issued and sold in the Rights Offering for net proceeds of approximately $44.8 million. Robert W. Duggan, the Company’s Chairman of the Board of Directors and the beneficial owner of approximately 35% of the Company’s outstanding common stock prior to the Rights Offering, participated in the Rights Offering and purchased an aggregate of 3,146,226 shares for an additional investment of approximately $39.5 million. Common Stock Warrants In connection with a private placement offering of the Company’s common stock, par value $0.001 per share in 2014, the Company issued warrants as compensation to the placement agent to purchase a total of 299,625 shares of its common stock at a price of $2.67 per share (the “Private Placement Warrants”). The Private Placement Warrants are exercisable for a period of seven years. As of March 31, 2019, there were a total of 91,876 Private Placement Warrants outstanding. In connection with the closing of the Company’s initial public offering in 2016, the Company issued warrants as compensation to its underwriters to purchase a total of 574,985 shares of its common stock at a price of $5.00 per share (“the IPO Warrants”). The IPO Warrants are exercisable for a period of five years. As of March 31, 2019 , there were a total of 121,609 of the IPO Warrants outstanding. Equity Plans 2017 Equity Incentive Plan and 2017 Inducement Equity Incentive Plan The Board of Directors of the Company (the “Board”) previously adopted, and the Company’s stockholders approved, the Company’s 2017 Equity Incentive Plan (the “2017 Plan”). The 2017 Plan has a 10 -year term, and provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, performance units, and performance shares to employees, directors and consultants of the Company and any parent or subsidiary of the Company, as the Compensation Committee of the Board may determine. Subject to an annual evergreen increase and adjustment in the case of certain capitalization eve nts, the Company initially reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to awards under the 2017 Plan. In addition, shares remaining under the Company’s 2015 Equity Incentive Plan, as amended (the “2015 Plan”), and shares reserved but not issued pursuant to outstanding equity awards that expire or terminate without being exercised or that are forfeited or repurchased by the Company will be added to the shares of common stock available for issuance under the 2017 Plan. The 2017 Plan is administered by the Board’s Compensation Committee. Effective January 1, 2019, the Company’s Board authorized an increase in the number of shares of common stock available under the 2017 Plan by 8 23,716 shares pursuant to the evergreen provision of the 2017 Plan. Pursuant to the 2017 Plan, the 2019 share increase is determined based on the least of (i) 1,200,000 shares, (ii) 4% of the Company’s common stock outstanding at December 31 of the immediately preceding year, or (iii) such number of shares as determined by the Board. As of March 31, 2019, 1,375,516 shares of common stock were available for issuance under the 2017 Plan. During November 2017, the Board adopted the 2017 Inducement Equity Incentive Plan (the “Inducement Plan”) and reserved 1,000,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. The Inducement Plan was adopted without stockholder approval. The Inducement Plan has a 10 -year term, and provides for the grant of equity-based awards, including nonstatutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance units, and its terms are substantially similar to the 2017 Plan, including with respect to treatment of equity awards in the event of a “merger” or “change in control” as defined under the Inducement Plan. Options issued under the Inducement Plan may have a term up to ten years and have variable vesting provisions. New hire grants generally vest 25% upon the first anniversary of the grant and 1/ 48th monthly thereafter, over the subsequent 36 months. E quity-based awards issued under the Inducement Plan are only issuable to individuals not previously engaged as employees or non-employee directors of the Company prior to the Inducement Plan’s adoption date. As of March 31, 2019, 515,250 shares of common stock were available for issuance under the Inducement Plan. 2017 Employee Stock Purchase Plan The Board previously adopted and the stockholders approved the Company’s 2017 Employee Stock Purchase Plan (the “2017 ESPP”). The 2017 ESPP is a broad-based plan that provides employees of the Company and its designated affiliates with the opportunity to become stockholders through periodic payroll deductions that are applied towards the purchase of Company common shares at a discount from the then-current market price. Subject to adjustment in the case of certain capitalization events, a total of 250,000 common shares of the Company were available for purchase at adoption of the 2017 ESPP. Pursuant to the 2017 ESPP, the annual share increase pursuant to the evergreen provision is determined based on the least of (i) 450,000 shares, (ii) 1.5% of the Company’s common stock outstanding at December 31 of the immediately preceding year, or (iii) such number of shares as determined by the Board. In January 2019, the Board determined not to increase the number of shares of common stock available under the 2017 ESPP pursuant to the evergreen provision of the 2017 ESPP. During the three-month period ended March 31, 2019, the Company issued 18,574 shares of common stock under the 2017 ESPP. As of March 31, 2019, 459,900 shares of common stock were available for issuance under the 2017 ESPP. A summary of stock option activity under the 2015 Plan, 2017 Plan and Inducement Plan for the three-months ended March 31, 2019 is presented below: Stock Options Outstanding Weighted Number average of shares exercise price Balances — December 31, 2018 2,956,687 $ 17.04 Options granted 174,303 Options exercised (98,928) Options canceled (9,667) Options expired (150,625) Balances — March 31, 2019 2,871,770 $ 17.22 Exercisable — March 31, 2019 1,446,422 $ 16.06 The table above excludes 42,500 performance stock options granted during the year ended December 31, 2018 for which the performance criteria had not been established as of March 31, 2019. Stock-based Compensation Total stock-based compensation expense consisted of the following (in thousands): Three-Month Periods Ended March 31, 2019 2018 General and administrative $ 1,485 $ 2,699 Research and development 876 721 Total stock-based compensation expense $ 2,361 $ 3,420 The Company estimated the fair value of employee stock options on the grant date using the Black-Scholes option pricing model . The estimated fair value of employee stock options is amortized on a straight-line basis over the requisite service period of the awards. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. Due to the limited trading history of the Company’s common stock, the Company utilizes a portfolio of comparable companies to estimate volatility. The fair value of employee stock options was estimated using the following weighted-average assumptions: Three-Month Periods Ended March 31, 2019 2018 Expected term in years 0.4 - 6.1 6.1 Expected volatility 70% 70% Risk-free interest rate 2.4 - 2.7% 2.7% Dividend yield — — The Company estimated the fair value of ESPP on the grant date using the Black-Scholes option pricing model . The estimated fair value of ESPP is amortized on a straight-line basis over the requisite service period of the awards. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. The Company utilizes its own volatility in the Black-Scholes option pricing model to determine the fair value of ESPP. The fair value of ESPP was estimated using the following weighted-average assumptions: Three-Month Periods Ended March 31, 2019 2018 Expected term in years 0.5 - 1.0 0.5 - 1.0 Expected volatility 70% 70% Risk-free interest rate 2.5% - 2.6% 1.9% - 2.1% Dividend yield — — The f air value of restricted stock unit (“RSUs”) awards is determined based on the number of units granted and the closing price of the Company’s common stock as of the grant date. The estimated fair value of RSUs is recognized on a straight-line basis over the requisite service period. In the three-month period ended June 30, 2017, the Company granted 160,974 RSUs all of which vested pursuant to which no shares were issued, during June 2018 . Additional paid in capital was reduced by $0.1 million during 2018 for tax payments related to shares withheld in connection with the vesting of the RSUs. As of March 31, 2019, there was no unrecognized compensation expense related to these RSUs. During the three-month period ended September 30, 2017, the Company granted 68,800 RSUs to certain employees which vest 50% on June 1, 2019 with the remaining 50% vesting on June 1, 2021 . In the event of a change in control, these RSUs vest 100% . The stock-based compensation expense related to these RSUs was approximately $0.1 m illion and $0.1 million for the t hree-month periods ended March 31, 2019 and March 31, 2018, respectively. |
Research Grants And Agreements
Research Grants And Agreements | 3 Months Ended |
Mar. 31, 2019 | |
Research Grants And Agreements [Abstract] | |
Research Grants And Agreements | 9. Research Grants and Agreements Sponsored Research Agreement The Company may annually sponsor research activities performed by ODURF’s Frank Reidy Research Center for Bioelectrics. During the year ended December 31, 2018, the Company agreed to sponsor $0.8 million in research during the subsequent 12 -month period to be funded through monthly payments made upon ODURF certifying, to the Company’s reasonable satisfaction, that ODURF has met its obligations pursuant to the specified task order and statement of work. The principal investigator may transfer funds with the budget as needed without the Company’s approval so long as the obligations of ODURF under the task order and statement of work remain unchanged and unimpaired. As of March 31, 2019, approximately $0.4 million remained payable under this sponsorship. In addition, during 2017, the Company agreed to provide $0.3 million in research funding to researchers affiliated with ODURF and Eastern Virginia Medical School matching funds made available to those researchers by the Virginia Biosciences Health Research Corporation. The Company’s sponsorship affords access to certain intellectual property, if any, developed during the project. As of March 31, 2019, approximately $0.1 million remained payable under this sponsorship. During the three-month periods ended March 31, 2019 and 2018, the Company paid and incurred costs relating to the sponsored research agreements equal to $0.2 million a nd $0.3 million, r espectively. |
Commitments And Contingencies
Commitments And Contingencies | 3 Months Ended |
Mar. 31, 2019 | |
Commitments And Contingencies [Abstract] | |
Commitments And Contingencies | 10. Commitments and Contingencies Operating Leases During January 2017, the Company entered into a new lease agreement for premises consisting of approximately 15,700 rentable square feet located in Hayward, California. The lease commenced on July 1, 2017 and expires in August 2022, with an option to extend the lease term for an additional five years . The Company adopted Topic 842 on January 1, 2019, using the transition method per ASU No. 2018-11 issued on July 2018 wherein entities were allowed to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Accordingly, all periods prior to January 1, 2019 were presented in accordance with the previous ASC 840, Leases, and no retrospective adjustments were made to the comparative periods presented. The adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets (“ROU”) presented within other assets and operating lease liabilities of approximately $0.1 million as of January 1, 2019 . Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. Information related to the Company's right-of-use assets and related lease liabilities were as follows : Cash paid for operating lease liabilities $ 132 Right-of-use assets recognized in exchange for new lease obligations 107 Current operating lease liabilities 396 Non-current operating lease liabilities 1,223 Total lease liabilities $ 1,619 Weighted average remaining lease term 3.42 years Weighted average discount rate 10% Maturities of lease liabilities as of March 31, 2019 were as follows (in thousands): Year Ending December 31: 2019 (remaining 9 months) $ 404 2020 554 2021 574 2022 392 Total lease payments 1,924 Less imputed interest (305) Total operating lease liabilities $ 1,619 During the three-month periods ended March 31, 2019 and 2018, rent expense, including common area maintenance charges, was approximately $59,000 and $57,000 , respectively. Legal Proceedings The Company maintains indemnification agreements with its directors and officers that may require the Company to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. From time to time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings relating to securities laws, product liability, patent infringement, contract disputes and other matters relating to various claims that arise in the normal course of our business in addition to governmental and other regulatory investigations and proceedings. In addition, third parties may, from time to time, assert claims against the Company in the form of letters and other communications. The Company currently believes that these ordinary course matters will not have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2019 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 11. Related Party Transactions Kenneth A. Clark, a director of the Company since November 2017, is a member of the law firm of Wilson Sonsini Goodrich and Rosati (“WSGR”), which also serves as the outside corporate counsel to the Company. During the three-month periods ended March 31, 2019 and 2018, the Company incurred expenses reported in general and administrative expenses in the consolidated statement of operations for legal services rendered by WSGR totaling approximately $0.2 million and $ 0.3 million , respectively . |
Summary Of Significant Accoun_2
Summary Of Significant Accounting Policies (Policy) | 3 Months Ended |
Mar. 31, 2019 | |
Summary Of Significant Accounting Policies [Abstract] | |
Basis Of Presentation | Basis of Presentation The accompanying unaudited condensed consolidated financial statements (“Financial Statements”) have been prepared on a basis consistent with the Company’s December 31, 2018 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Financial Statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated balance sheet as of December 31, 2018 was derived from the audited consolidated financial statements as of that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. The results of operations for the three-month period ended March 31, 2019 are not necessarily indicative of the results to be expected for the entire year or any future periods. |
Use Of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes to the Financial Statements. Estimates include, but are not limited to, the valuation of cash equivalents and investments, the valuation and recognition of share-based compensation and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates. |
Recent Adopted Accounting Pronouncement | Recently Adopted Accounting Pronouncement In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“Topic 842”), which amended prior accounting standards for leases. The Company adopted Topic 842 on January 1, 2019, using the transition method per ASU No. 2018-11 issued on July 2018 wherein entities were allowed to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Accordingly, all periods prior to January 1, 2019 were presented in accordance with the previous ASC 840, Leases, and no retrospective adjustments were made to the comparative periods presented. The adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets (“ROU”) presented within other assets and operating lease liabilities of approximately $0.1 million as of January 1, 2019. The adoption did not materially impact the Company’s Consolidated Statement of Stockholders’ Equity or Cash Flows. |
Significant Accounting Policies | Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies during the three-month period ended March 31, 2019, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, except for the adoption of ASU No. 2016-02, Leases , as of January 1, 2019. |
Principles of Consolidation | Principles of Consolidation The accompanying consolidated financial statements include the financial statements of Pulse Biosciences and its wholly-owned subsidiaries. Intercompany balances and transactions, if any, have been eliminated in consolidation. |
Net Loss Per Share | Net Loss per Share The Company calculates basic net loss per share by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share. Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive. The following outstanding stock options, warrants and restricted stock units were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three-Month Periods Ended March 31, 2019 2018 Common stock warrants 213,485 249,709 Common stock options 2,871,770 2,598,754 Restricted stock units 222,606 229,774 Total 3,307,861 3,078,237 |
Reclassification | Reclassification Certain items in prior period financial statements have been reclassified to conform to the presentation in the current period financial statements. Such reclassifications did not impact the Company's previously reported net loss or financial position. |
Summary Of Significant Accoun_3
Summary Of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Summary Of Significant Accounting Policies [Abstract] | |
Anti-Dilutive Shares Excluded From Computation Of Diluted Net Loss Per Share | Three-Month Periods Ended March 31, 2019 2018 Common stock warrants 213,485 249,709 Common stock options 2,871,770 2,598,754 Restricted stock units 222,606 229,774 Total 3,307,861 3,078,237 |
Fair Value Of Financial Instr_2
Fair Value Of Financial Instruments (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Fair Value Of Financial Instruments [Abstract] | |
Fair Value Of Financial Assets Measured On A Recurring Basis | March 31, 2019 December 31, 2018 Assets Classification Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Money market funds Cash and cash equivalents $ 7,773 — — $ 7,773 $ 50,703 $ — $ — $ 50,703 U.S. Treasury Securities Investments — 44,265 — 44,265 — 8,480 — 8,480 Total assets measured at fair value $ 7,773 $ 44,265 $ — $ 52,038 $ 50,703 $ 8,480 $ — $ 59,183 |
Property And Equipment, Net (Ta
Property And Equipment, Net (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Property And Equipment, Net [Abstract] | |
Schedule Of Property And Equipment, Net | March 31, December 31, 2019 2018 Leasehold improvements $ 2,248 $ 2,248 Laboratory equipment 589 518 Furniture, fixtures, and equipment 256 248 Software 117 118 Construction in progress — 33 3,210 3,165 Less: Accumulated depreciation (1,154) (992) $ 2,056 $ 2,173 |
Intangible Assets, Net (Tables)
Intangible Assets, Net (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Intangible Assets, Net [Abstract] | |
Schedule Of Intangible Assets, Net | March 31, December 31, 2019 2018 Acquired patents and licenses $ 7,985 $ 7,985 Less: Accumulated amortization (2,939) (2,772) $ 5,046 $ 5,213 |
Schedule Of Amortization Of Intangible Assets | Year Ending December 31: 2019 (remaining 9 months) $ 499 2020 665 2021 665 2022 665 2023 665 2024 665 Thereafter 1,222 $ 5,046 |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Accrued Expenses [Abstract] | |
Schedule Of Accrued Expenses | March 31, December 31, 2019 2018 Compensation expense $ 672 $ 938 Accrued clinical 429 156 Professional fees 315 274 Supplies 28 53 Other 75 — $ 1,519 $ 1,421 |
Stockholders' Equity And Stoc_2
Stockholders' Equity And Stock-Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Stockholders' Equity [Line Items] | |
Summary Of Stock Option Activity | Stock Options Outstanding Weighted Number average of shares exercise price Balances — December 31, 2018 2,956,687 $ 17.04 Options granted 174,303 Options exercised (98,928) Options canceled (9,667) Options expired (150,625) Balances — March 31, 2019 2,871,770 $ 17.22 Exercisable — March 31, 2019 1,446,422 $ 16.06 |
Schedule Of Fair Value Of Employee Stock Options | Three-Month Periods Ended March 31, 2019 2018 Expected term in years 0.4 - 6.1 6.1 Expected volatility 70% 70% Risk-free interest rate 2.4 - 2.7% 2.7% Dividend yield — — |
Summary Of Stock-Based Compensation Expense | Three-Month Periods Ended March 31, 2019 2018 General and administrative $ 1,485 $ 2,699 Research and development 876 721 Total stock-based compensation expense $ 2,361 $ 3,420 |
2017 Employee Stock Purchase Plan [Member] | |
Stockholders' Equity [Line Items] | |
Schedule Of Fair Value Of Employee Stock Options | Three-Month Periods Ended March 31, 2019 2018 Expected term in years 0.5 - 1.0 0.5 - 1.0 Expected volatility 70% 70% Risk-free interest rate 2.5% - 2.6% 1.9% - 2.1% Dividend yield — — |
Commitments And Contingencies (
Commitments And Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Commitments And Contingencies [Abstract] | |
Schedule Of Information Related To Right-Of-Use Assets And Lease Liabilities | Cash paid for operating lease liabilities $ 132 Right-of-use assets recognized in exchange for new lease obligations 107 Current operating lease liabilities 396 Non-current operating lease liabilities 1,223 Total lease liabilities $ 1,619 Weighted average remaining lease term 3.42 years Weighted average discount rate 10% |
Schedule Of Future Minimum Lease Payments | Year Ending December 31: 2019 (remaining 9 months) $ 404 2020 554 2021 574 2022 392 Total lease payments 1,924 Less imputed interest (305) Total operating lease liabilities $ 1,619 |
Summary Of Significant Accoun_4
Summary Of Significant Accounting Policies (Narrative) (Details) $ in Millions | Jan. 01, 2019USD ($) |
Accounting Standards Update 2016-02 [Member] | |
Summary Of Significant Accounting Policies [Line Items] | |
Increase in total assets and liabilities due to recording of operating lease right-of-use assets and operating lease liabilities | $ 0.1 |
Summary Of Significant Accoun_5
Summary Of Significant Accounting Policies (Anti-Dilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details) - shares | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 3,307,861 | 3,078,237 |
Warrants to purchase common stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 213,485 | 249,709 |
Options outstanding [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 2,871,770 | 2,598,754 |
Restricted Stock Units [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 222,606 | 229,774 |
Fair Value Of Financial Instr_3
Fair Value Of Financial Instruments (Narrative) (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Fair Value Of Financial Instruments [Abstract] | ||
Liabilities measured at fair value | $ 0 | $ 0 |
Transfers between level 1, 2, or 3 | $ 0 |
Fair Value Of Financial Instr_4
Fair Value Of Financial Instruments (Fair Value Of Financial Assets Measured On A Recurring Basis) (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
ASSETS | ||
Total assets measured at fair value | $ 52,038 | $ 59,183 |
Cash and cash equivalents [Member] | Money market funds [Member] | ||
ASSETS | ||
Total cash and cash equivalents | 7,773 | 50,703 |
Investments [Member] | U.S. Treasury Securities [Member] | ||
ASSETS | ||
Total investments | 44,265 | 8,480 |
Level 1 [Member] | ||
ASSETS | ||
Total assets measured at fair value | 7,773 | 50,703 |
Level 1 [Member] | Cash and cash equivalents [Member] | Money market funds [Member] | ||
ASSETS | ||
Total cash and cash equivalents | 7,773 | 50,703 |
Level 2 [Member] | ||
ASSETS | ||
Total assets measured at fair value | 44,265 | 8,480 |
Level 2 [Member] | Investments [Member] | U.S. Treasury Securities [Member] | ||
ASSETS | ||
Total investments | $ 44,265 | $ 8,480 |
Property And Equipment, Net (Na
Property And Equipment, Net (Narrative) (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Property And Equipment, Net [Abstract] | ||
Depreciation expense | $ 162 | $ 153 |
Property And Equipment, Net (Sc
Property And Equipment, Net (Schedule Of Property And Equipment, Net) (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Property, Plant and Equipment [Line Items] | ||
Equipment, gross | $ 3,210 | $ 3,165 |
Less: Accumulated depreciation | (1,154) | (992) |
Equipment, net | 2,056 | 2,173 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Equipment, gross | 2,248 | 2,248 |
Laboratory Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Equipment, gross | 589 | 518 |
Furniture, Fixtures, And Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Equipment, gross | $ 256 | 248 |
Software [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Equipment, gross | $ 33 |
Intangible Assets, Net (Narrati
Intangible Assets, Net (Narrative) (Details) | 3 Months Ended |
Mar. 31, 2019 | |
Intangible Assets, Net [Abstract] | |
Intangible asset useful life | 12 years |
Intangible Assets, Net (Schedul
Intangible Assets, Net (Schedule Of Intangible Assets, Net) (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Finite-Lived Intangible Assets [Line Items] | ||
Less: Accumulated amortization | $ (2,939) | $ (2,772) |
Intangible assets, net | 5,046 | 5,213 |
Acquired Patents And Licenses [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Intangible assets, gross | $ 7,985 | $ 7,985 |
Intangible Assets, Net (Sched_2
Intangible Assets, Net (Schedule Of Amortization Of Intangible Assets) (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Intangible Assets, Net [Abstract] | ||
2019 (remaining 9 months) | $ 499 | |
2020 | 665 | |
2021 | 665 | |
2022 | 665 | |
2023 | 665 | |
2024 | 665 | |
Thereafter | 1,222 | |
Intangible assets, net | $ 5,046 | $ 5,213 |
Goodwill (Narrative) (Details)
Goodwill (Narrative) (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2019 | Dec. 31, 2014 | Dec. 31, 2018 | |
Business Acquisition, Equity Interests Issued or Issuable [Line Items] | |||
Goodwill | $ 2,791,000 | $ 2,800,000 | $ 2,791,000 |
Goodwill impairment | $ 0 | ||
TPI, BEM And NB [Member] | |||
Business Acquisition, Equity Interests Issued or Issuable [Line Items] | |||
Aggregate consideration | $ 5,500,000 |
Accrued Expenses (Schedule Of A
Accrued Expenses (Schedule Of Accrued Expenses) (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Accrued Expenses [Abstract] | ||
Compensation expense | $ 672 | $ 938 |
Accrued clinical | 429 | 156 |
Professional fees | 315 | 274 |
Supplies | 28 | 53 |
Other | 75 | |
Accrued expenses | $ 1,519 | $ 1,421 |
Stockholders' Equity And Stoc_3
Stockholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands | Dec. 06, 2018 | Jan. 01, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | Sep. 30, 2017 | Dec. 31, 2017 | Dec. 31, 2014 | Dec. 31, 2018 | Oct. 25, 2018 | Nov. 30, 2017 | Jun. 30, 2017 | Dec. 31, 2016 |
Stockholders' Equity [Line Items] | ||||||||||||
Common stock, par value | $ 0.001 | $ 0.001 | ||||||||||
Common stock, shares issued | 20,710,000 | 20,593,000 | ||||||||||
Total stock-based compensation expense | $ 2,361 | $ 3,420 | ||||||||||
Cash received from option exercises | $ 222 | 112 | ||||||||||
2017 Employee Stock Purchase Plan [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Common stock, shares issued | 18,574 | |||||||||||
Shares authorized | 250,000 | |||||||||||
Additional common stock reserved for issuance | 459,900 | |||||||||||
Increase in shares available for issuance threshold of common stock outstanding, number of shares | 450,000 | |||||||||||
Increase in shares available for issuance threshold of common stock outstanding, percent outstanding | 1.50% | |||||||||||
2017 Inducement Equity Incentive Plan [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Term period | 10 years | |||||||||||
Shares authorized | 515,250 | 1,000,000 | ||||||||||
2017 Plan [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Term period | 10 years | |||||||||||
Shares authorized | 1,500,000 | |||||||||||
Additional common stock reserved for issuance | 823,716 | 1,375,516 | ||||||||||
Increase in shares available for issuance threshold of common stock outstanding, number of shares | 1,200,000 | |||||||||||
Increase in shares available for issuance threshold of common stock outstanding, percent outstanding | 4.00% | |||||||||||
First Vesting Portion [Member] | 2017 Inducement Equity Incentive Plan [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Vesting percentage | 25.00% | |||||||||||
Second Vesting Portion (Per Month) [Member] | 2017 Inducement Equity Incentive Plan [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Vesting period | 36 months | |||||||||||
Vesting percentage | 0.02% | |||||||||||
Sales, general and administrative [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Total stock-based compensation expense | $ 1,485 | 2,699 | ||||||||||
Research and development [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Total stock-based compensation expense | $ 876 | 721 | ||||||||||
Options outstanding [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Options granted | 174,303 | |||||||||||
Warrants exercised | 98,928 | |||||||||||
Exercise price | $ 16.06 | |||||||||||
Restricted Stock Units [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Shares available for grant | 68,800 | |||||||||||
Total stock-based compensation expense | $ 100 | $ 100 | ||||||||||
Restricted Stock Units [Member] | First Vesting Portion [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Vesting percentage | 50.00% | |||||||||||
Cliff vest date | Jun. 1, 2019 | |||||||||||
Restricted Stock Units [Member] | Second Vesting Portion (Per Month) [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Vesting percentage | 50.00% | |||||||||||
Cliff vest date | Jun. 1, 2021 | |||||||||||
Restricted Stock Units [Member] | Change In Control [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Vesting percentage | 100.00% | |||||||||||
Officer [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Cliff vest date | Jun. 30, 2018 | |||||||||||
Officer [Member] | Restricted Stock Units [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Shares available for grant | 160,974 | |||||||||||
Common Stock | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Warrants exercised | 99,000 | 38,000 | ||||||||||
Common Stock | Rights Offering [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Net proceeds | $ 44,800 | |||||||||||
Right entitlement to holder | 3,581,148 | 0.19860755 | ||||||||||
Exercise price of warrants/rights | $ 12.57 | |||||||||||
Common Stock | Chairman, Robert W. Duggan [Member] | Rights Offering [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Ownership percentage | 35.00% | |||||||||||
Shares purchased | 3,146,226 | |||||||||||
Investment | $ 39,500 | |||||||||||
MDB Capital Group, LLC [Member] | Initial Public Offering [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Price per share | $ 5 | |||||||||||
Warrants/rights outstanding | 121,609 | |||||||||||
Exercisable period of warrants or rights | 5 years | |||||||||||
Number of common shares called by issuance of warrants | 574,985 | |||||||||||
MDB Capital Group, LLC [Member] | Private Placement [Member] | ||||||||||||
Stockholders' Equity [Line Items] | ||||||||||||
Price per share | $ 2.67 | |||||||||||
Warrants/rights outstanding | 91,876 | |||||||||||
Exercisable period of warrants or rights | 7 years | |||||||||||
Number of common shares called by issuance of warrants | 299,625 |
Stockholders' Equity And Stoc_4
Stockholders' Equity And Stock-Based Compensation (Summary Of Stock Option Activity) (Details) - Options outstanding [Member] | 3 Months Ended |
Mar. 31, 2019$ / sharesshares | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | |
Beginning Balance, Number of shares | shares | 2,956,687 |
Options granted, Number of shares | shares | 174,303 |
Options exercised, Number of shares | shares | (98,928) |
Options canceled, Number of shares | shares | (9,667) |
Options expired, Number of shares | shares | (150,625) |
Ending Balance, Number of shares | shares | 2,871,770 |
Exercisable, Number of shares | shares | 1,446,422 |
Beginning Balance, Weighted average exercise price per share | $ / shares | $ 17.04 |
Options granted, Weighted average exercise price per share | $ / shares | |
Options exercised, Weighted average exercise price per share | $ / shares | |
Options canceled, Weighted average exercise price per share | $ / shares | |
Options expired, Weighted average exercise price per share | $ / shares | |
Ending Balance, Weighted average exercise price per share | $ / shares | 17.22 |
Exercisable, Weighted average exercise price per share | $ / shares | $ 16.06 |
Stockholders' Equity And Stoc_5
Stockholders' Equity And Stock-Based Compensation (Schedule Of Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Stock-based compensation | $ 2,361 | $ 3,420 |
Sales, general and administrative [Member] | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Stock-based compensation | 1,485 | 2,699 |
Research and development [Member] | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Stock-based compensation | $ 876 | $ 721 |
Stockholders' Equity And Stoc_6
Stockholders' Equity And Stock-Based Compensation (Schedule Of Fair Value Of Employee Stock Options) (Details) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Options outstanding [Member] | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected volatility | 70.00% | 70.00% |
Risk-free interest rate | 2.70% | |
Risk-free interest rate, minimum | 2.40% | |
Risk-free interest rate, maximum | 2.70% | |
Dividend yield | ||
Options outstanding [Member] | Minimum [Member] | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected term in years | 4 months 24 days | 6 years 1 month 6 days |
Risk-free interest rate | 2.70% | |
Options outstanding [Member] | Maximum [Member] | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected term in years | 6 years 1 month 6 days | |
2017 Employee Stock Purchase Plan [Member] | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected volatility | 70.00% | 70.00% |
Risk-free interest rate, minimum | 2.50% | 1.90% |
Risk-free interest rate, maximum | 2.60% | 2.10% |
Dividend yield | ||
2017 Employee Stock Purchase Plan [Member] | Minimum [Member] | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected term in years | 6 months | 6 months |
2017 Employee Stock Purchase Plan [Member] | Maximum [Member] | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected term in years | 1 year | 1 year |
Stockholders' Equity And Stoc_7
Stockholders' Equity And Stock-Based Compensation (Summary Of Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Total stock-based compensation expense | $ 2,361 | $ 3,420 |
Sales, general and administrative [Member] | ||
Total stock-based compensation expense | 1,485 | 2,699 |
Research and development [Member] | ||
Total stock-based compensation expense | $ 876 | $ 721 |
Research Grants And Agreements
Research Grants And Agreements (Narrative) (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
Research and development expense | $ 5,842 | $ 3,175 | |
Sponsored Research Agreement ("SRA") [Member] | |||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
Research and development expense | $ 200 | $ 300 | |
ODURF [Member] | |||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
Period of time for Sponsored Research Agreement ("SRA") | 12 months | ||
ODURF [Member] | Sponsored Research Agreement ("SRA") [Member] | |||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
Research and development expense | $ 800 | ||
Remaining sponsorship | $ 400 | ||
ODURF And Eastern Virginia Medical School [Member] | Sponsored Research Agreement ("SRA") [Member] | |||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
Research and development expense | $ 300 | ||
Remaining sponsorship | $ 100 |
Commitments And Contingencies_2
Commitments And Contingencies (Narrative) (Details) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2019USD ($) | Mar. 31, 2018USD ($) | Jan. 31, 2017ft² | |
Commitments And Contingencies [Abstract] | |||
Area Of Lease | ft² | 15,700 | ||
Rent expense, including common area maintenance charges | $ | $ 59 | $ 57 |
Commitments And Contingencies_3
Commitments And Contingencies (Schedule Of Information Related To Right-Of-Use Assets And Lease Liabilities) (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Commitments And Contingencies [Abstract] | |
Cash paid for operating lease liabilities | $ 132 |
Right-of-use assets recognized in exchange for new lease obligations | 107 |
Current operating lease liabilities | 396 |
Non-current operating lease liabilities | 1,223 |
Total lease liabilities | $ 1,619 |
Weighted average remaining lease term | 3 years 5 months 1 day |
Weighted average discount rate | 10.00% |
Commitments And Contingencies_4
Commitments And Contingencies (Schedule Of Future Minimum Lease Payments) (Details) $ in Thousands | Mar. 31, 2019USD ($) |
Commitments And Contingencies [Abstract] | |
2019 (remaining 9 months) | $ 404 |
2020 | 554 |
2021 | 574 |
2022 | 392 |
Total minimum lease payments | 1,924 |
Less imputed interest | (305) |
Total operating lease liabilities | $ 1,619 |
Related Party Transactions (Nar
Related Party Transactions (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions | Dec. 06, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | Oct. 25, 2018 |
Related Party Transaction [Line Items] | |||||
Common stock, par value | $ 0.001 | $ 0.001 | |||
Wilson Sonsini Goodrich And Rosati (WSGR) [Member] | |||||
Related Party Transaction [Line Items] | |||||
Related party expenses | $ 0.2 | $ 0.3 | |||
Common Stock | Rights Offering [Member] | |||||
Related Party Transaction [Line Items] | |||||
Right entitlement to holder | 3,581,148 | 0.19860755 | |||
Exercise price of warrants/rights | $ 12.57 | ||||
Net proceeds | $ 44.8 | ||||
Common Stock | Chairman, Robert W. Duggan [Member] | Rights Offering [Member] | |||||
Related Party Transaction [Line Items] | |||||
Ownership percentage | 35.00% |